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Abstract Epilepsy is associated with a higher rate of prema-
ture death than the general population, and the commonest
cause of epilepsy mortality is sudden unexpected death in
epilepsy (SUDEP). It is difficult to quantify because of the
variable reporting of this cause of death. Death occurs due to
autonomic deregulation of cardio-respiratory pathways as a
result of seizures. Measures to reduce cardio-respiratory dys-
function are discussed together with the importance of seizure
control in preventing SUDEP. The role of seizure detection
devices, antiepileptic drugs and the importance of providing
information about SUDEP to people with epilepsy are
highlighted. There is increasing interest in SUDEP and some
current initiatives are discussed.
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Introduction
Epilepsy is the most common serious neurological condition,
affecting almost 60 million people worldwide [1]. People with
epilepsy may be two to three times more at risk of dying
prematurely as a result of their illness when compared to a
normal population [2], and sudden death in people with epi-
lepsy is over 20 times more frequent than in the general
population [3].
Sudden unexpected death in epilepsy (SUDEP) is an un-
common but tragic consequence of epilepsy. SUDEP has
received considerable examination over the last 10 years with
a revision of the definition, an attempt to more accurately
estimate the true incidence, a better understanding of the
mechanisms and risk factors leading to death, and how the
risk of SUDEP is discussed with patients and families. Sig-
nificant funding is currently available from the National Insti-
tute for Health with SUDEP being the subject of a Centre
without Walls call in 2014. This followed the research recom-
mendations of The National Institute for Health/National In-
stitute for Neurological Disease and Stroke Workshop on
SUDEP in 2011 [4]. There are significant challenges associ-
ated with research into sudden death in epilepsy. This paper
will outline how SUDEP is now defined, the difficulties in
case ascertainment as a result of variable reporting and the
difficulties this imposes on estimates of incidence. The mech-
anisms of SUDEP are described, and how improved under-
standing of why SUDEP occurs may lead to effective risk
reduction strategies and finally how the risk may be reduced.
Defining SUDEP
SUDEP was first defined nearly 20 years ago and since then,
two complimentary definitions have been in use [5, 6]. It is
important to unify the definition to reduce ambiguity and to
retrieve cases that would not have been studied using the
earlier definition. It is proposed that the term ‘unexpected’
should be used rather than ‘unexplained’ that SUDEP should
be categorised where appropriate and an additional category
of SUDEP plus should be designated when it is likely that a
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pre-existing condition could have contributed to death. To be
considered SUDEP, the death should have occurred within an
hour of the terminal event and status epilepticus as an exclusion
criterion is when the seizure duration is more than 30 min [7•].
Definite SUDEP can be used when a post-mortem examination
shows no definite cause of death, probable SUDEP when post-
mortem examination is not performed but other criteria are
fulfilled and possible SUDEP is applied when a competing
cause of death is present. Near SUDEP is sometimes used in
cases where death is likely to have occurred if resuscitation
or other interventions had not been applied [4–6, 7•].
Reporting SUDEP
SUDEP is the main cause of death in individuals with epilepsy
but the term is underused in death certification [8]. The post-
mortem examination of sudden death from any cause is prob-
lematic and requires a careful and detailed interrogation of
families and witnesses to identify past medical history, symp-
toms, medication use [9] and circumstances leading up to
death. This is particularly important in the light of sub-
optimal reporting.
A UK study examined 612 death entries (60 % male), with a
median age of 35. Four hundred and ninety-eight had undergone
post-mortem examination, of which 44 stated that SUDEP was
the cause of death and 292 were considered probable SUDEP.
They found 69 were attributable to status epilepticus, with a
further 71 epilepsy-related deaths. Close examination of the
documentation suggested that nearly half of the cases attributed
to status epilepticus are more appropriately classified as SUDEP
and that status epilepticus as a cause of death should only be
recorded if there is a documented history of uncontrolled sei-
zures. The conclusion was that correct certification of death is
essential to provide accurate data on SUDEP and other epilepsy
deaths and to ensure a more accurate picture of the prevalence of
SUDEP [10]. Similar problems were identified in the USA. A
retrospective evaluation of forensic autopsy cases 2007–2009
was conducted in the State of Maryland, which has 15 medical
examiners (MEs). One hundred and four sudden unexpected
deaths which were directly or indirectly caused by epilepsy or
seizure disorder were found, of which 74 met the definition of
SUDEP. However, of the 74 cases, seizure disorder was listed as
the primary cause of death in 65 cases and epilepsy as the
primary cause in 1, with SUDEP being listed at the primary
cause of death in only 8 cases. It was found that despite 14/
15 MEs acknowledging SUDEP as a valid diagnosis, only
two used SUDEP as an official cause of death, with the
majority preferring to use seizure disorder or epilepsy rath-
er than a term that was felt to imply some uncertainty
around the diagnosis [11].
A survey about the use of the diagnosis of SUDEP as a
cause of death was administered to all coroners and medical
examiners in the USA.While 83.5% of pathologists acknowl-
edged SUDEP as a valid diagnosis if no cause of death is
found at autopsy, only 22.9 % went on to use SUDEP in cases
eligible for the diagnosis, irrespective of their educational
background, location, autopsy rate or number of seizure cases
seen and conclude that SUDEP appears to be underused as a
final diagnosis by MEs throughout the USA [8].
If the correct cause of death can be reported on certificates,
the true incidence of SUDEP may be found to be much higher
than currently reported [12]. Following the increasing aware-
ness of SUDEP, in 2013, two American states (New Jersey
and Illinois) signed SUDEP measures into law requiring med-
ical examiners to find out about potential history of epilepsy as
part of the autopsy. It remains to be seen if this example is
followed by other states but the need for better education
concerning SUDEP is clear [3].
Incidence of SUDEP
In population-based studies, the stated incidence range from
0.09 to 2.31/1000 patient-years [13] and this rate is higher in
patients with refractory epilepsy awaiting assessment for a
surgical programme [14] at 9.3/1000 patient-years. A study
of a cohort of children diagnosed with epilepsy in 1964 from
Finland, where there is a high rate of autopsy, observed over
40 years showed a rate of SUDEP of 7 % overall and 12 %
excluding patients in remission [15]. A prospective audit of
4578 patients with epilepsy in the mid-west of the USA over
5 years collected data from 16,463 patient-years. One hundred
and eleven patients died in this period of which 10 were
judged to be definite SUDEP and 10 probable SUDEP. This
gave an overall incidence of SUDEP of 1.21/1000 patient-
years with the highest incidence in the 50–59 age range [16].
A retrospective study of mortality in Epilepsy Monitoring
Units (EMU) demonstrated a total SUDEP incidence of 5·1
(95 % CI 2·6–9·2) per 1000 patient-years and suggests that
SUDEP could be associated with suboptimum supervision
and antiepileptic drug withdrawal [17•]. This study identified
160 EMU in Europe, Australia, New Zealand and Israel and
achieved a 92% survey response rate with data collected from
an estimated 133,788 video electroencephalogram (VEEG)
and analysed in subgroups of age and reason for monitoring.
There was only one SUDEP/near SUDEP case in children and
the total rate of adult SUDEP/near SUDEP was 7.9 (4.6–
12.7), 9.7 (5.2–16.7) in pre-surgical assessment and 4.9
(4.6–12.7) per 1000 patient-years in ‘other VEEG’ monitored
cases [17•].
Given the complex judgements required in defining defi-
nite/probable/possible/near SUDEP and the variable standards
of post mortem investigation and death certification, it is
difficult to accurately calculate the incidence of SUDEP. To
draw out more concrete data, a systematic review of incidence
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papers is currently being carried out by an international group
convened by the American Association of Neurologists
(AAN) to review all available data and preliminary results
from this review show the incidence of SUDEP to depend on
type and severity of epilepsy with an overall incident rate
range for the general epilepsy population, including children
and adults, estimated at 0.7–1.5 per 1000 patient-years, inclu-
sive of refractory patients (personal communication Harden).
This review should provide useful sub-group analysis to in-
form future work in this area.
Reducing the Risk of SUDEP
Reducing the risk of SUDEP requires an understanding of
why it happens, how it happens, how to detect and address
prodromal events and how to control seizures. There are,
however, no clear cut answers.
Understanding the Mechanisms Underlying SUDEP
The substantial work published on identifying a mechanism
suggests that there are overlapping cardiac, respiratory and
autonomic domains but no clear evidence for pre-existing
pathway or structural abnormalities [18]. Demonstrating this
overlap, the MORTEMUS study sheds new light on a previ-
ously unrecognised pattern (termed early postictal
neurovegetative breakdown) from observed SUDEP with ini-
tial generalized tonic-clonic seizure (GTCS) triggering a short
period of normal or increased heart and respiratory rates then
severe bradycardia and central apnoea with post-ictal EEG
suppression that is fatal in a third of cases. In those who
survive the initial impact, there is transient improvement of
cardiac function but associated with abnormal and ineffective
respiration that can be aggravated by the prone position before
terminal apnoea followed by terminal asystole [17•].
Autonomic dysfunction resulting in poor homeostatic re-
sponses has also been implicated in sudden infant death syn-
drome (SIDS) with overstimulation of the adenosine receptors
[19] and a defect in 5-HT brainstem-mediated control of
respiratory and autonomic regulation [20]. In animal models,
progressive neuronal loss as a result of convulsions has been
noted, for example, in the nucleus tractus solitarius (NTS) (the
afferent autonomous gatekeeper) and sclerosis of the lateral
amygdaloid nuclei [21], and may play a role in impairing the
integrative functions of the NTS resulting in poor homeostatic
responses during seizures and leading to SUDEP [22]. Dys-
function of the 5-HT axis can lower the seizure threshold and
increase the risk of depression and sudden death, and this
pathophysiological mechanism may be shared with SIDS.
The converse is true in that an increase in extracellular 5-HT
may raise the seizure threshold [23]. 5-HT affects many other
cerebral functions, including arousal, thermoregulation,
circadian rhythms, anxiety, pain, aggression and respiratory
control, and may be a factor in the similarities between
SUDEP and SIDS [24]. However, research is needed to trans-
late these findings perhaps into the development of agents that
enhance serotonin (5-HT) to reduce seizures and SUDEP. One
promising avenue is the selective serotonin reuptake inhibitors
(SSRI). Fluoxetine was found to reduce respiratory depression
in patients undergoing telemetry [25] and reduction of respi-
ratory depression in seizure induced mice [26]. It may be that
agents such as fluoxetine can reduce the risk of SUDEP [27].
Cardiac dysfunction may also provide clinical markers for
SUDEP [28]. In particular, reduced heart rate variability
(HRV) may be a predisposing factor for SUDEP [29]. A re-
analysis of this study showed that there are differences be-
tween high-frequency HRV [30] and a further study of 19
individuals showed an association between HRVand SUDEP
risk [31] and this association with progressive deterioration of
HRV was noted in a case report [32].
Heart rate variability leads strength to the proposal that all
patients with epilepsy should have an assessment of their car-
diac function to rule out channelopathies. There is some support
for the hypothesis of single ion channel mutation (KCNA1
gene) that could underlie both epilepsy and cardiac arrhythmias
[3]. The association between epilepsy and cardiac function
suggest that omega 3 fatty acids may be of benefit given a
number of studies having shown the consumption of fatty fish
may reduce the number of sudden cardiac deaths, and a number
of animal and clinical studies suggest that omega-3 fatty acids
may be useful in the prevention and treatment of epilepsy [33].
Seizure Detection Devices
Seizure detection systems can be used to alert observers to
intervene to reduce the effects of seizures. The most sophisti-
cated monitoring system combines video and EEG recording.
This complex system is labour intensive and usually limited to
in-patient hospital use. There is a growing demand for mon-
itoring devices that can be used in the home to detect seizures
to enable arousal interventions to prevent SUDEP. A number
of devices are available and may measure motor activity [34],
measure cardiovascular or respiratory changes, detect associ-
ated autonomic changes through electro-dermal activity, audio
detection, temperature, ocular and eyelid movements, body
pressure or moisture [1].
Devices need to be able to reliably detect seizure activity,
but if the device gives false-positive alarms that affects sleep,
it becomes unacceptable to the individual and observers.
Given the individual nature of seizures, the most effective
way to detect seizures may be to use a combination of sys-
tems. While acknowledging the gold standard for monitoring
epileptic seizures continues to be video/EEG, which takes
place in controlled environments such as EpilepsyMonitoring
Units (EMUs), there are other body signals that can be
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monitored and the response in terms of monitoring and detec-
tion systems that are available. There are a range of body
movements that can be monitored to detect seizure activity,
but that the detection systems must be non-invasive, multi-
modal and appropriate to use in a domestic setting [1] .
A prospective study of a flexible movement monitor tested on
children over 2 years with a monitor designed to fit under a
mattress and attached to amonitor [35]. The study team tested the
monitor in a hospital setting with concurrent EEG, cardiopulmo-
nary and nursemonitoring. Seventy-eight seizures were recorded
by EEG videos in 45 patients. The monitor captured 30 % of all
seizure events, 54% of events while sleeping and 85%ofGTCS
while sleeping. The alarm was not sensitive to seizures with no
rhythmical movements. A similar mattress monitor study in
patients aged 13–65 years with tonic-clonic seizures demonstrat-
ed the need for individual calibration [36, 37]. The potential
benefit of a mattress detection device for GTCS in 79 patients
(after excluding 28 patients because of a faulty sensor or inaccu-
rate recording of data) showed a PPVof 0.43 and NPVof 0.98.
Awrist-worn wireless accelerometer has been shown to be
useful in detecting GTCS with a low false-positive rate [37].
The authors suggest further work is required on a larger group
of patients in an ambulatory setting. However, results were
disappointing in a prospective study of two bed alarms for
detection of nocturnal seizures with only one GTCS detected
out of 15 seizures while sleeping [38]. Given the search for
effective home-based seizure monitoring and the need for an
individualised multi-modal system, convincing evidence for
non-EEG systems is still awaited [1].
Controlling Seizures with Antiepileptic Drugs
Antiepileptic drugs (AEDs) remain the treatment of choice in
controlling seizures [39] and thereby eliminating the risk of
SUDEP. However, while there have been studies that raised
concerns about specific drugs and therapeutic regimes, the
evidence is unconvincing [16, 40]. Indeed, a meta-analysis
of 97 papers investigating any AED adjunct treatment of drug-
resistant epilepsy suggests that adjunctive AED at efficacious
doses reduce the incidence of definite or probable SUDEP by
more than seven times compared to placebo and so provides
evidence in favour of active treatment for patients with refrac-
tory epilepsy [41]. A commentary on the issues raised by this
important paper [42] reinforces the safety of adjunct therapies
and the risks to patients in placebo arms of comparative studies.
AEDs are most effective when they are taken as prescribed.
Non-adherence to medicines leads to reduced drug levels and
has been implicated in sub-optimal management [43] and
SUDEP [44, 11]. Non-adherence to medicines has been iden-
tified as a factor in cases of SUDEP [45, 46]. Medicine non-
adherence is a dynamic and variable behaviour and so patients’
use of medicine should be reviewed on a regular basis [47]. To
do this, the patient needs to be a partner in decisions about
treatment and this requires information about the impact of the
condition.When patients are aware of the risks associated with
epilepsy including SUDEP, they are given an opportunity to
take decisions to reduce that risk, particularly in how they
manage their epilepsy and take their AED [48, 49•].
Optimising Self-Management by Understanding the Risks
Associated with Epilepsy
For many years, there was reluctance by some health pro-
fessionals to talk openly about SUDEP. However, the
weight of opinion is shifting to full disclosure. A call for
openness on SUDEP, encouraging early discussion of risk,
was backed by an international expert panel and 14 inter-
national epilepsy organisations at the 30th International
Epilepsy Congress in Montreal held in 2013 (www.sudep.
org/article/sudepactionleadscallforopenness2013).
In response to calls for disclosure and discussion, many health
professionals are unsure how to respond. This suggests that the
philosophy of self-management and informed decision-making
have not been universally adopted into epilepsy care. The SUDEP
debate has injected some urgency into discussion on howepilepsy
education generally should take place, something which is long
overdue [50]. To assist health professionals to respond, a report
from the joint working party of the American Epilepsy Society
and Epilepsy Foundation summarises risks and preventative strat-
egies [51]. In particular, information about SUDEP is important
for patients at risk of AED non-adherence and for those who are
candidates for surgery and can be reassuring for patients with
well-controlled epilepsy who are at low risk.
Discussion
The challenge of preventing sudden death from epilepsy is
currently receiving more attention than previously with in-
creasing numbers of research publications and conference
posters relating to SUDEP. There is a SUDEP Special Interest
Group within the AES, and Partners Against Mortality in
Epilepsy (PAME) held their second international meeting in
Minneapolis USA in 2014. This conference attracted partici-
pants from across the world and included bereaved families,
researchers and clinicians. SUDEP is now a subject for dis-
closure and discussion, and in recognition of this more open
approach, SUDEP Registries have been established for
reporting by professionals (www.sudep.org/) and from
families (http://epilepsydeathsregister.org/) (www.
sudepaware.org/) (www.epilepsyireland.org/) to provide a
wider collection of data concerning cases.
By revisiting the definition, it should provide clearer guid-
ance for certificating SUDEP as the cause of death and for
epidemiologists involved in population-based studies by
standardising the datasets. Only by doing this will the true
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incidence be uncovered. The progress made in describing
mechanisms of death allows the term unexplained to be
discarded. The element of doubt is incorporated in the defini-
tion with definite, probable and possible being included. Near-
SUDEP is most likely to be recorded in events observed and
remedied in EMU but it must not be forgotten that although
SUDEP is more common in patients with refractory epilepsy,
it can and does occur in patients viewed as being at low risk.
These cases will only be recorded if good post-mortem prac-
tice is more widespread, and it is encouraging that two states
in the USA have made it mandatory for MEs to gather infor-
mation about epilepsy. This essential instruction to coroners
and MEs must become commonplace.
The precise mechanism of SUDEP is still unknown but the
MORTEMUS study gives a novel insight into the progression
of events described as post-ictal neurovegetative breakdown.
Cardiac monitoring, prevention of respiratory depression and
cardiac function by manipulation of the autonomic pathways
by SSRI co-prescribing and omega 3 supplements may be
valuable avenues for exploration.
In those people where seizure control is unachievable, then,
seizure monitoring can be undertaken. The methods must be
individualised and sensitive enough to avoid poor compliance
due to false alarms and acceptable for home use. There is no
single best device and effective monitoring may require a
multi-modal approach. This presents a challenge of afford-
ability and complexity.
It is reassuring that a meta-analysis of adjunct AED therapy
shows the benefit of polytherapy in efficacious doses. Previous
evidence about the association of adjunct AED and SUDEP
seems to be the result of epilepsy severity rather than caused by
polytherapy. Of concern is the risk of SUDEP in patients
attending EMUwho are in the placebo phase of the assessment
and the necessarily rapid AED withdrawal in these patients. If
evidence relating to the safety of slower tapering of dose is
available then a case for longer in-patient stay could be made.
Where good seizure control is possible, there is a need for
continuing and open discussion about decisions in respect of
management, particularly in regard to medicines non-adher-
ence. This is a common behaviour and yet not fully discussed
or assessed during the consultation. This could be a key to
reducing risk and is made easier with the information available
from not-for-profit organisations. The development of regis-
ters of epilepsy-related death offers an opportunity for some-
thing positive to come out of such a tragic event and all
involved in the care of people with epilepsy may wish to
signpost the bereaved to these important initiatives.
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